IRIS
POTESTIO, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 9.173
NA - Nord America 4.884
EU - Europa 4.702
SA - Sud America 1.039
AF - Africa 221
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 2
Totale 20.039
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.699
SG - Singapore 4.060
RU - Federazione Russa 2.285
CN - Cina 2.214
VN - Vietnam 1.111
BR - Brasile 834
DE - Germania 735
HK - Hong Kong 593
IT - Italia 495
NL - Olanda 378
IN - India 368
FR - Francia 266
KR - Corea 250
JP - Giappone 188
GB - Regno Unito 123
FI - Finlandia 91
MX - Messico 88
AR - Argentina 80
CA - Canada 67
BD - Bangladesh 60
CI - Costa d'Avorio 59
ZA - Sudafrica 53
IE - Irlanda 52
UA - Ucraina 47
IQ - Iraq 43
EC - Ecuador 42
PL - Polonia 37
ES - Italia 34
PH - Filippine 34
PK - Pakistan 31
AT - Austria 29
TR - Turchia 29
ID - Indonesia 27
TH - Thailandia 23
MA - Marocco 21
SE - Svezia 20
JO - Giordania 18
PY - Paraguay 18
VE - Venezuela 17
UZ - Uzbekistan 15
EG - Egitto 14
TW - Taiwan 14
BG - Bulgaria 13
CO - Colombia 13
KE - Kenya 13
LT - Lituania 13
AU - Australia 12
CL - Cile 12
DZ - Algeria 12
AZ - Azerbaigian 11
IL - Israele 10
PE - Perù 10
MY - Malesia 9
RO - Romania 9
SA - Arabia Saudita 9
UY - Uruguay 9
PT - Portogallo 8
TN - Tunisia 8
BE - Belgio 7
RS - Serbia 7
AE - Emirati Arabi Uniti 6
AL - Albania 6
DO - Repubblica Dominicana 6
KZ - Kazakistan 6
OM - Oman 6
CZ - Repubblica Ceca 5
EE - Estonia 5
ET - Etiopia 5
PS - Palestinian Territory 5
SK - Slovacchia (Repubblica Slovacca) 5
AM - Armenia 4
BO - Bolivia 4
CR - Costa Rica 4
DK - Danimarca 4
GR - Grecia 4
LB - Libano 4
PA - Panama 4
SY - Repubblica araba siriana 4
BA - Bosnia-Erzegovina 3
BB - Barbados 3
CH - Svizzera 3
CM - Camerun 3
HU - Ungheria 3
KG - Kirghizistan 3
KH - Cambogia 3
ML - Mali 3
MR - Mauritania 3
NP - Nepal 3
NZ - Nuova Zelanda 3
AF - Afghanistan, Repubblica islamica di 2
BH - Bahrain 2
BW - Botswana 2
CG - Congo 2
CV - Capo Verde 2
GE - Georgia 2
GH - Ghana 2
GN - Guinea 2
HN - Honduras 2
HR - Croazia 2
KW - Kuwait 2
Totale 19.989
Salva come PNG Salva come JPEG
Città #
Singapore 2.071
Hefei 1.186
San Jose 1.025
Moscow 582
Hong Kong 570
Ashburn 483
Secaucus 458
Santa Clara 412
Ho Chi Minh City 351
Beijing 338
Amsterdam 314
Hanoi 235
Seoul 226
Kochi 215
Lauterbourg 181
Chandler 176
Tokyo 167
The Dalles 141
Los Angeles 136
Krefeld 118
Redondo Beach 95
Dallas 93
Naples 90
São Paulo 76
Buffalo 63
Munich 63
New York 61
Council Bluffs 55
Frankfurt am Main 49
Milan 49
Mexico City 46
Helsinki 45
Bad Bellingen 43
Boston 42
Da Nang 40
Rome 39
Seattle 39
Orem 38
Haiphong 36
Chennai 35
Dublin 35
Chicago 32
Falkenstein 30
Lawrence 30
Rio de Janeiro 29
Warsaw 29
Lappeenranta 28
Nuremberg 28
Atlanta 27
Montreal 27
Johannesburg 22
Biên Hòa 21
Brooklyn 21
London 21
Brasília 20
Denver 20
Belo Horizonte 18
Houston 18
Millbury 18
Poplar 18
Shanghai 18
Turku 18
Amman 17
Florence 17
Hải Dương 17
Kronberg 17
Pune 17
Stockholm 17
Mumbai 16
Boardman 15
Phoenix 15
Quito 15
Baghdad 14
Curitiba 14
Menlo Park 14
Tashkent 14
Arezzo 13
Bengaluru 13
Guangzhou 13
Düsseldorf 12
Guayaquil 12
Lahore 12
Nairobi 12
Washington 12
Madrid 11
Salvador 11
Sofia 11
Toronto 11
Turin 11
Vienna 11
Xi'an 11
Baku 10
Ciudad del Este 10
Erbil 10
Fairfield 10
Manchester 10
Porto Alegre 10
Qingdao 10
Rochdale 10
Wilmington 10
Totale 11.495
Salva come PNG Salva come JPEG
Nome #
A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis 1.026
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study 393
Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications 170
A practical guide to recognize allergic and immunologic skin diseases: diagnosis at first sight 166
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study 151
Clinical, trichoscopic and in vivo reflectance confocal microscopy evaluation of alopecia areata in atopic dermatitis patients treated with dupilumab 146
Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study 140
Airborne and systemic allergic contact dermatitis due to corticosteroids 131
Zosteriform leiomyomas after Herpes Zoster infection: the isotopic pathway 131
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience 129
Comment on ‘Anogenital dermatology: challenges in the digital era’ 128
The use of ChatGPT in the dermatological field: a narrative review 127
Real-world practice indirect comparison between guselkumab, risankizumab and tildrakizumab: results from an Italian 28-week retrospective study 127
Letter to the editor regarding article "Falotico JM, Gu L, Lipner SR. Not just pimple popping: The utility of hybrid telemedicine models beyond acne management amidst the ongoing COVID-19 pandemic. J Cosmet Dermatol. 2022;10.1111/jocd.15256" 126
Corrigendum: A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab (Clin Cosmet Investig Dermatol. (2023), 16, (3503–3507), 10.2147/CCID.S447123) 126
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 126
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 126
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review 125
A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab 123
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature 123
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature 122
Management of Psoriasis Patients with Serious Infectious Diseases 122
Reply to: Upadacitinib for the management of overlapping psoriasis and atopic dermatitis: a case series 121
The impact of COVID ‐19 infection on psoriatic patients treated with biologics: an Italian experience 121
Scabies outbreak during COVID-19: an Italian experience 120
Alcohol flushing during dupilumab therapy: an emerging adverse event 120
Risk Factors for Psoriasis Flares: A Narrative Review 117
Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation 117
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge 117
Reply to 'Cutaneous adverse effects of the available COVID-19 vaccines in India: A questionnaire-based study' by Bawane J et al 116
Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis 116
Teledermatology: a useful tool also after Covid-19 era? 116
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis 115
Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real‐life study 114
The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review 114
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection 114
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis) 114
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas 113
Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study 113
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature 112
Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: a retrospective analysis 112
Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study 112
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders 112
Kaposi's sarcoma as presentation of HIV in an atopic patient treated with upadacitinib 111
Dermatophytid evaluated by in vivo reflectance confocal microscopy: a new approach? 110
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation 109
Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation 108
Letter to the editor regarding article "Yalici-Armagan B, Tabak GH, Dogan-Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1-5" 108
JAK Inhibitors in Psoriatic Disease 107
Unaddressed Challenges in the Treatment of Cutaneous Melanoma? 107
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials 106
Effects of COVID-19 pandemic on malignant melanoma diagnosis 106
The effects of dupilumab treatment on general health-related work productivity of adult atopic patients 106
The Risk of Herpes Virus Infection in Patients With Atopic Dermatitis During Biologic Therapy: A Retrospective Records Based Observational Study 105
Long-term efficacy of telemedicine for patients with locally advanced basal cell carcinoma during COVID-19 pandemic 105
The impact of body mass index on dupilumab treatment outcomes in adult atopic dermatitis patients 105
Allergic contact dermatitis probably due to brimonidine tartrate in eyedrops 105
Letter to the editor regarding article "Oguz Topal I, Kara Polat A, Zindancı İ, et al. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study. J Cosmet Dermatol. 2021;10.1111/jocd.14610." 105
Immune response to Covid‐19 mRNA vaccination in psoriasis patients undergoing treatment with biologics 105
Abrocitinib in atopic dermatitis: review of the current literature and clinical trials 104
Acrodermatitis continua of Hallopeau: is apremilast an efficacious treatment option? 104
Dietary intervention in acne management: review of the literature and future prospective 103
Hidradenitis Suppurativa Cancer Risk: A Review of the Literature 103
Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma 103
Granuloma annulare after SARS-CoV-2 vaccination: A case report and a literature review 103
Comment on ‘Pityriasis rubra pilaris-like eruption following mRNA COVID-19 vaccine’ 102
Reply to “A case of symmetrical drug‐related intertriginous and flexural exanthema‐like eruption associated with Pfizer COVID ‐19 vaccination” by Manaa et al 102
Considerations for managing elderly patients with atopic dermatitis 102
A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab 102
Alitretinoin for the treatment of severe chronic eczema of the hands 102
Lichen planus following Covid-19 vaccination: a narrative review 101
Letter to the editor submitted in response to ‘Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study’ 101
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis 101
Reply to “Nail psoriasis: a rare mRNA COVID ‐19 vaccine reaction” by Lamberti A et al 101
Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study 101
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 101
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities 100
Comment on ‘Permethrin-unresponsive scabies in London, UK: a wake-up call’ 99
Guselkumab-induced vitiligo in a patient with psoriatic arthritis 98
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? 98
Efficacy and Safety of bimekizumab in psoriasis management in real-life: bio-naïve vs bio-experienced 98
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond 98
New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge? 98
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature 97
Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris 97
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review 97
Comment on: “Clinical characteristics of patients with pityriasis rubra pilaris following SARS‐CoV‐2 vaccination” by Gambichler 97
A case of acne fulminans successfully treated with photodynamic therapy 97
Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations 97
Reply to "A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine" 96
Comment on: "Associations between hidradenitis suppurativa and dermatological conditions in adults: A national cross-sectional study by Brown et al." 96
Assessment of the efficacy, skin acceptability and cosmetic quality of an adjuvant cream based on 40% urea and amino-inositol in the treatment of mild psoriasis 96
Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? 96
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab 95
Efficacy and safety of upadacitinib in adult patients affected by moderate to severe atopic dermatitis: a 16-week real-life dual-centre experience 94
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study 94
Dupilumab for the treatment of adult atopic dermatitis in special populations 93
Comment on 'Morphoea following COVID-19 vaccination' 93
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation 92
Tralokinumab in elderly atopic dermatitis 92
Totale 12.262
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.211
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.211
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 0 3 0 3
2021/2022317 18 5 12 8 17 2 5 31 71 51 33 64
2022/2023616 37 31 20 49 55 70 55 72 72 29 72 54
2023/20241.259 38 92 83 68 52 90 28 114 343 43 179 129
2024/20256.072 252 324 86 60 162 404 496 468 434 772 2.043 571
2025/202612.050 1.234 2.183 1.330 1.268 1.708 749 1.072 875 1.233 398 0 0
Totale 20.320